Monte Rosa Q2 2026 earnings: Higher R&D widens loss as pipeline advances

Monte Rosa Therapeutics (Nasdaq: GLUE) reported Q2 2026 collaboration revenue of $9.0 million, down from $23.2 million a year earlier, while net loss widened to $43.4 million from $12.3 million. The larger loss reflected lower collaboration revenue and higher R&D spending as the company advanced multiple clinical programs; it ended June with $626.0 million in cash, restricted cash and marketable securities.

Core Financial Results

Collaboration revenue, which came from agreements with Roche and Novartis, declined by approximately 61% year over year. At the same time, R&D expense rose by approximately 56%, primarily because of increased spending on MRT-8102 and other development and discovery programs.

The combination of lower revenue and higher operating expenses widened the operating loss by $33.6 million. Interest income of $5.9 million partially offset the operating loss before taxes.

Losses are shown as absolute amounts. R&D and G&A expenses included stock-based compensation of $3.3 million and $2.7 million, respectively.

Clinical Pipeline Progress

MRT-8102 advances toward multiple Phase 2 studies

Monte Rosa completed enrollment and dosing in the GFORCE-1 Phase 1 study of MRT-8102 in people with elevated cardiovascular disease risk. The study tested multiple dose levels over four weeks, followed by four weeks of safety monitoring, with results expected in the second half of 2026.

In data previously reported in January, MRT-8102 produced an 85% median reduction in C-reactive protein after four weeks. The forthcoming update is expected to include additional inflammatory and cardiometabolic biomarkers, including calprotectin.

The company plans three Phase 2 studies across elevated atherosclerotic risk and cardiometabolic syndrome, recurrent gout flares, and moderate-to-severe hidradenitis suppurativa. This broad development plan also helps explain the increase in R&D spending during the quarter.

Novartis activates an MRT-6160 Phase 2 study

Novartis activated a Phase 2a/b study of MRT-6160, also known as DDY391, in participants with Sjögren’s disease. Monte Rosa expects a milestone payment after the first patient visit, although the amount was not disclosed.

Under the global license agreement, Monte Rosa is eligible for up to $2.1 billion in contingent development, regulatory and sales milestones. Novartis is responsible for funding and conducting Phase 2 studies. Monte Rosa would co-fund Phase 3 development and share 30% of U.S. manufacturing and commercialization profits and losses, while remaining eligible for tiered royalties outside the U.S.

MRT-2359 moves into Phase 2

Monte Rosa activated the MODeFIRe-1 Phase 2 study of MRT-2359 in combination with apalutamide for metastatic castration-resistant prostate cancer patients with androgen receptor mutations. The study will initially include up to 25 patients and may expand into other patient subsets.

The company also completed enrollment of six patients with androgen receptor mutations in an initial Phase 1/2 expansion arm evaluating MRT-2359 with enzalutamide. An update from this group is planned by year-end.

Higher Pipeline Spending Widens Losses, While Cash Provides a Multiyear Runway

Cash, cash equivalents, restricted cash and marketable securities declined to $626.0 million at June 30 from $671.2 million at March 31. The $45.2 million sequential reduction was primarily attributed to operational use of cash.

The decline was broadly consistent with a quarter in which operating expenses reached $58.1 million and several programs moved toward or into Phase 2 development. Management expects the remaining cash position to support operations into 2029, providing time for multiple planned clinical readouts and study initiations. However, that runway remains an estimate and will depend partly on the cost and timing of the expanding trial portfolio.

Guidance and Development Milestones

Monte Rosa’s forward outlook centers on its cash runway and clinical development calendar rather than revenue or earnings targets. The nearest major catalyst is the GFORCE-1 MRT-8102 readout expected in the second half of 2026.

Novartis is also expected to initiate multiple MRT-6160 Phase 2 studies in immune-mediated diseases during 2026.

Recent Insider Transactions

According to the supplied insider transaction data, insiders purchased 128,460 shares across 16 transactions and sold 179,077 shares across 23 transactions during the latest six-month period. That represents net sales of 50,617 shares, or 9.6% of reported insider holdings, with total insider holdings listed at approximately 478,150 shares.

The ten most recent reported transactions include a combination of derivative-security exercises and direct sales.

These transactions do not, by themselves, establish insiders’ views on Monte Rosa’s future prospects.

Risks Investors Should Monitor

• Clinical readout risk: MRT-8102’s GFORCE-1 results are a central near-term catalyst. The planned Phase 2 program depends on successfully translating earlier biomarker findings into broader evidence across multiple dose levels and endpoints.
• Rising development costs: R&D expense increased to $48.0 million as Monte Rosa advanced its portfolio. Starting several Phase 2 trials could increase cash requirements and affect the projected runway.
• Variable collaboration revenue: Quarterly revenue depends on collaboration and licensing arrangements. The decline from $23.2 million to $9.0 million demonstrates that recognized collaboration revenue can fluctuate materially between periods.
• Partner execution and contingent payments: MRT-6160 milestones depend on study initiations and other development events under the Novartis partnership. Potential milestone amounts, including the stated maximum of $2.1 billion, are contingent rather than guaranteed revenue.
• Limited oncology dataset: The initial MRT-2359 expansion arm included six patients with androgen receptor mutations, making the year-end update important but based on a small group.

Summary

Monte Rosa’s Q2 2026 results showed the financial effects of advancing a clinical-stage pipeline: collaboration revenue declined while R&D spending increased, widening the quarterly net loss. The company’s $626.0 million cash position provides a projected runway into 2029, while investor attention now shifts to the MRT-8102 GFORCE-1 readout, several planned Phase 2 starts, MRT-2359 oncology data and execution under the Novartis partnership.